Deloitte Corporate Finance LLC Advises MedCart LTC, Inc. dba MedCart Specialty Pharmacy in its Sale

CHARLOTTE, N.C., Oct. 3, 2017 /PRNewswire/ -- Deloitte Corporate Finance LLC acted as the exclusive financial advisor to MedCart LTC, Inc. dba MedCart Specialty Pharmacy (MedCart), a closed-door, URAC accredited, specialty pharmacy based in Livonia, Michigan, in its sale to an Idaho-based food and drug retailer. The transaction closed May 26, 2017.

"MedCart's reputation for its best-in-class patient management programs across a variety of disease states created an attractive match with the acquirer," said Doug Bolt, managing director, Deloitte Corporate Finance LLC. "Advising MedCart on such a pivotal moment in the Company's history was an absolute privilege," Bolt added.

"Deloitte Corporate Finance's experience and hands-on approach provided invaluable guidance throughout the transaction process. We are excited for our next phase of growth as our business principles and goals complement our new partner, benefiting everyone involved in the partnership--most importantly our patients," said Eddie Abueida, co-founder and co-chief executive officer of MedCart Specialty Pharmacy.

"We've worked hard to create an infrastructure that serves patients and providers with the utmost in quality specialty care services and coordination that are required for these medications," said Ed Saleh, RPh, co-founder and co-chief executive officer of MedCart Specialty Pharmacy. "Our new partnership presents an excellent opportunity for us to extend our mission to more patients."

About MedCart Specialty Pharmacy
MedCart Specialty Pharmacy is a closed-door specialty pharmacy with URAC Specialty Pharmacy 3.0 Accreditation. Based in Michigan, the Company provides services across a wide variety of disease states with a focus on HIV, Hepatitis C Virus, and inflammatory diseases. For more information, visit www.medcartpharmacy.com.

About Deloitte Corporate Finance LLC
Deloitte Corporate Finance LLC (DCF) provides strategic advisory services and M&A advice that help corporate, entrepreneurial and private equity clients create and act upon opportunities for liquidity, growth and long-term advantage. With an in-depth understanding of the marketplace and access to a global network of investment bankers, DCF advises clients in both domestic and global markets. DCF, together with the Corporate Finance Advisory practices within the Deloitte Touche Tohmatsu Limited network of member firms, include in excess of 1,900 professionals, who work collaboratively across 150 international locations. With our significant experience providing investment banking services across key industries, we are able to offer our clients solutions that help them to achieve their strategic objectives. For more information, visit www.investmentbanking.deloitte.com.

For media inquiries, please contact:
Shelley Pfaendler
Public Relations
Deloitte Services LP
+1 212 492 4484
spfaendler@deloitte.com

Prior engagement performance is no guarantee of future performance and may not be representative of the experience of other clients. This communication is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security.

Deloitte Corporate Finance LLC, an SEC registered broker-dealer and member of FINRA and SIPC, is an indirect wholly-owned subsidiary of Deloitte Financial Advisory Services LLP and affiliate of Deloitte Transactions and Business Analytics LLP. Investment banking products and services within the United States are offered exclusively through Deloitte Corporate Finance LLC. For more information, visit www.investmentbanking.deloitte.com. Please see www.deloitte.com/us/about for a detailed description of our legal structure. Certain services may not be available to attest clients under the rules and regulations of public accounting.

View original content with multimedia:http://www.prnewswire.com/news-releases/deloitte-corporate-finance-llc-advises-medcart-ltc-inc-dba-medcart-specialty-pharmacy-in-its-sale-300529985.html

SOURCE Deloitte